Jill Wechsler, Pharm Exec’s Washington Correspondent

Jill Wechsler is Pharm Exec's Washington Corespondent


Congress Slated to Reauthorize User Fees, Without FDA ‘Improvements’

Seek pared-down measure in funding bill to avert shutdown.

Clinical Trial Modernization Raises FDA Compliance Issues

Agency officials express associated concerns around clinical trial data reliability and quality.

Advanced Biopharma Manufacturing Key to White House Cancer Moonshot

Administration launches national manufacturing initiative, with aim to reduce US reliance on biomedicine from China and other regions.

FDA in Limbo as User Fee Renewal Stuck on Capitol Hill

In countdown to renewal deadline, agency already feeling the effects of still-unclear legislative fate.

Senate Advances Drug Price Negotiations

Democrats approve curbs for Medicare plans, but not for commercial drug coverage.